In patients with COVID-19 and moderate-to-severe hypoxemic respiratory failure, high-flow oxygen is as effective as helmet noninvasive ventilation in patients who show PaO2/[FiO2*VAS dyspnea]≥30 and/or PaCO2≥35 mmHg under conventional oxygen, while helmet noninvasive ventilation as applied in the HENIVOT trial may improve clinical outcome among subjects exhibiting PaO2/[FiO2*VAS dyspnea]<30 and/or PaCO2<35 mmHg.

Phenotypes of Patients with COVID-19 Who Have a Positive Clinical Response to Helmet Noninvasive Ventilation

Maggiore, Salvatore Maurizio;
2022-01-01

Abstract

In patients with COVID-19 and moderate-to-severe hypoxemic respiratory failure, high-flow oxygen is as effective as helmet noninvasive ventilation in patients who show PaO2/[FiO2*VAS dyspnea]≥30 and/or PaCO2≥35 mmHg under conventional oxygen, while helmet noninvasive ventilation as applied in the HENIVOT trial may improve clinical outcome among subjects exhibiting PaO2/[FiO2*VAS dyspnea]<30 and/or PaCO2<35 mmHg.
File in questo prodotto:
File Dimensione Formato  
rccm.202105-1212le.pdf

accesso aperto

Descrizione: Correspondence
Tipologia: PDF editoriale
Dimensione 620.72 kB
Formato Adobe PDF
620.72 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/761788
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 22
social impact